Rx Product News

Published Online: Wednesday, October 9, 2013
Follow Pharmacy_Times:


Marketed by: Forest Laboratories, Inc.
Indication: The FDA has approved Fetzima (levomilnacipran), a serotonin and norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Fetzima is not approved for the management of fibromyalgia. The recommended dose is 40 to 120 mg once daily with or without food. Dosing should be initiated by taking 20 mg once daily for 2 days. Capsules should be swallowed whole.
Dosage Form: Extended-release capsules: 20, 40, 80, and 120 mg
For More Information: https://fetzima.com

Marketed by: Silvergate Pharmaceuticals, Inc
Indication: The FDA has approved Epaned (enalapril), an angiotensin-converting enzyme inhibitor for the treatment of hypertension in adults and children older than 1 month. The recommended initial dose in adults is 5 mg once daily, with a maximum dose of 40 mg/day. In children, the recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily.
Dosage Form: Powder for oral solution: 150 mg of enalapril maleate in a 150 mL bottle; reconstitution with 150 mL of ORA-SWEET SF results in a 1 mg/mL oral solution
For More Information: www.SilvergatePharma.com

Marketed by: Takeda Pharmaceuticals America, Inc
Indication: The FDA has approved Oseni—a dipeptidyl peptidase-4 inhibitor and thiazolidinedione combination product—as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Oseni is not indicated for treating type 1 diabetes mellitus or diabetic ketoacidosis. The starting dose should be individualized to the patient, but a daily dose of alogliptin 25 mg and pioglitazone 45 mg should not be exceeded.
Dosage Form: Tablets (mg alogliptin/mg pioglitazone): 25/15, 25/30, 25/45, 12.5/15, 12.5/30, 12.5/45
For More Information: www.takeda.us/products/default.aspx

FluLaval Quadrivalent

Marketed by: GlaxoSmithKline
Indication: The FDA has approved FluLaval Quadrivalent, a vaccine indicated for active immunization to prevent disease caused by influenza A subtype viruses and type B viruses in persons 3 years and older. The recommended dose in children 3 through 8 years of age who have not been vaccinated against influenza is 2 doses (0.5 mL each) at least 4 weeks apart. For more details, see the manufacturer’s prescribing information.
Dosage Form: Suspension for injection in 5-mL multidose vials containing ten 0.5-mL doses
For More Information: http://us.gsk.com/html/medicines/index.html#vaccineshttp://us.gsk.com/products/assets/us_flulaval_ quadrivalent.pdf

Related Articles
Avella Specialty Pharmacy announced today that it has been selected by GlaxoSmithKline as one of a select group of pharmacies authorized to continue to distribute Benlysta, a medication approved by the FDA for the treatment of systemic lupus erythematosus in patients who have previously received other therapies.
Mylan has announced the US launch of its lamivudine tablets, the generic version of GlaxoSmithKline's hepatitis B virus (HBV) treatment, Epivir-HBV.
Evidence released by the manufacturers of Tamiflu and Relenza has raised questions concerning the drugs' efficacy and safety.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times